Adaptive Biotechnologies Corp(ADPT)股价今日盘中大涨9.93%,引发市场关注。
股价上涨主要受到机构评级目标价上调的利好消息驱动。投行Scotiabank维持对ADPT的评级为"跑赢大盘",并将目标价从10美元上调至12美元。此前,ADPT在生物技术行业内表现出较强的发展势头。
作为一家专注于免疫驱动医学的生物科技公司,ADPT的临床诊断产品clonoSEQ已获FDA批准,可用于检测和监测多种血液肿瘤患者的最小残留病情。ADPT正着力将该产品推广至更广泛的淋巴癌适应症。公司在血液肿瘤诊断领域的创新有望为长期增长注入新动能。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.